Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
A Phase 1, Multicenter, Open-label, Non-randomized, Dose-escalation and Backfill Study of KK2223 in Participants With Relapsed or Refractory T-cell Non Hodgkin Lymphoma
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory periphe…
T-cell NHL (PTCL or CTCL)
Estimated
~$10 – $8,750
Kyowa Kirin, Inc.NCT07192471
Phase 1
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monot…
LymphomaNon-Hodgkin LymphomaHodgkin Lymphoma+4 more
Estimated
~$10 – $7,500
AstraZenecaNCT06137144
Phase 1
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-…
LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma+10 more
Estimated
~$10 – $7,500
Phase 2
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral…
PTCL
Estimated
~$10 – $6,250
University of VirginiaNCT04747236